2. Brewer's yeast (Saccharomyces cerevisiae)
The evolutionary fermentation miracle — high chromium, B-complex, and the residual value of alcohol maturation.
Brewer's yeast in 1 minute
What does it provide? B-vitamin complex (B1, B2, B3, B5, B6, biotin, folate — the classic Goldberger anti-pellagra source, but does NOT produce B12), chromium-niacin-amino acid complex (GTF = glucose tolerance factor, improves insulin sensitivity), selenium, β-glucan (cell-wall immune-modulator polysaccharide), and ≈ 45% protein. Saccharomyces cerevisiae ≠ Candida albicans (taxonomically different) and ≠ S. boulardii (which is a separate probiotic strain).
How much? 1–2 tbsp (10–20 g) inactivated, debittered (flavor-mellowed) powder in yogurt, smoothie, soup added LATER (NOT cooked long — B vitamins are heat-labile). Acne regimen Weber 2012 RCT: 2 g per day for 8–12 weeks combined with zinc. Chromium GTF T2D support (Anderson 1997): ≈ 200 µg chromium/day, under medical supervision.
When to avoid? MAO inhibitor treatment + ACTIVE (live) brewer's yeast (classic tyramine "cheese effect" — hypertensive crisis); active gout and hyperuricemia (high purine: 300–500 mg/100 g); celiac disease, if barley-derived (choose molasses-medium gluten-free product); active Crohn's with ASCA positivity; immunocompromised state with ACTIVE yeast (rarely documented fungemia); do NOT use as sole B12 source in vegan diet. Detailed contraindications in the dedicated section.
Medicinal use of brewer's yeast goes back to the early 19th century: French and German physicians used it around 1860 for digestive disorders, skin problems (acne, eczema), and "nervous fatigue" — based on empirical experience, knowing that "something in the beer wort" helped, without naming the vitamin. The breakthrough is associated with American physician Joseph Goldberger: his research in the southern USA in the 1910–20s proved that pellagra (the classic "4D" — dermatitis, diarrhoea, dementia, death) is a deficiency disease, NOT an infection, and treatable with brewer's yeast supplementation. Goldberger in 1915 essentially eliminated pellagra in orphanages and prisons with brewer's yeast supplementation [2604] — a classic milestone in modern medicine's recognition of nutritionally deficient diet.
The 1937 Conrad Elvehjem discovery (nicotinic acid = B3 = niacin) scientifically named the component that Goldberger had used empirically [2605]. In the 1950–60s folk medicine, brewer's yeast was the "natural B-vitamin pill" — consumed as a spoonful of powder or in tablets. In Central European pharmacies, "brewer's yeast tablets" were a non-prescription staple for decades for acne, brittle nails, and "spring fatigue." In the 21st century the brewer's yeast trend declined (fortified grains and multivitamins took over the B-vitamin replacement role), but it is still used in certain sports and diabetology circles for chromium glucose tolerance factor (GTF), and S. boulardii-as-probiotic flourishes as a separate category (Florastor, Enterol).
Scientific Background
Brewer's yeast is the same species — Saccharomyces cerevisiae — as nutritional yeast, but different strain and processing: as a brewing by-product or purposely grown on molasses medium, traditionally bitter (from hop-derived iso-α-acids) flavor — sold in debittered form as food supplements. CRITICAL difference vs. nutritional yeast: brewer's yeast is typically NOT fortified with B12, so NOT suitable for B12 replacement — the most common lay error.
B-vitamin content: brewer's yeast is naturally rich in B1, B2, B3, B5, B6, biotin, and folate. 1 tablespoon (~10 g) provides 30–50% of the RDI for B1, B2, B3, B5 — a meaningful deficiency-replacement source. B12, however, is essentially absent (Watanabe 2014: yeast does not produce cobalamin) [2597]. This made brewer's yeast the primary natural therapy for pellagra (B3 deficiency) in the first half of the 20th century — Goldberger empirically, then Elvehjem (1937) with molecular evidence.
Chromium and glucose tolerance factor (GTF): brewer's yeast contains a biologically active chromium-niacin-amino acid complex, identified by Walter Mertz in 1959 as "glucose tolerance factor." In Anderson et al. (1997, Diabetes) GTF reduced fasting insulin and improved glucose tolerance in T2D [2606]. Modern RCTs are inconsistent — the chromium GTF hypothesis is modestly supported, with weak-moderate effect size, and chromium picolinate supplement is not equivalent to the GTF complex [2607].
Acne: Weber et al. (2012, J Am Acad Dermatol) in a small-sample study showed hydrolysis-stabilized brewer's yeast (CBS 5926 / CBS17 strain) reduced acne vulgaris lesion counts over 8 weeks — interesting, but needs replication [2608].
Upper respiratory infection: S. cerevisiae β-glucan in concentrated form (Wellmune) RCTs showed seasonal cold-frequency reduction [2600] — this effect concerns concentrated β-glucan supplement, not raw brewer's yeast.
IMPORTANT taxonomic difference: Saccharomyces cerevisiae ≠ Candida albicans! The two yeast species are molecularly and clinically different. Brewer's yeast consumption does NOT feed Candida — the wellness myth does not hold.
Saccharomyces boulardii — this is a separate probiotic strain of S. cerevisiae (Florastor, Enterol) — proven effective in antibiotic-associated diarrhea and IBS (McFarland 2010) [2610]. This is NOT classic brewer's yeast, and don't confuse them!
Safety: ACTIVE (live) brewer's yeast in MAO inhibitor treatment accumulates tyramine — hypertensive crisis risk (classic "cheese effect") [2612]. In gout, high purine content (300–500 mg/100 g) can raise uric acid [2601].
- + B12 supplement or fortified nooch: because brewer's yeast does NOT provide B12! In vegan/vegetarian regimen, combined supplementation needed.
- + Chromium target: 1–2 tbsp brewer's yeast extract + ~200 µg chromium/day Anderson 1997 protocol for T2D support: under medical supervision.
- + Acne target: 8–12 week regimen Weber 2012 protocol combined with zinc.
- + Smoothie, yogurt, soup matrix: bitter flavor maskable with lemon or honey.
- + Nail strengthening: 3–6 month regimen for biotin content.
- + With food (NOT empty stomach): better tolerance, less gastric irritation.
- + In celiac disease, choose brewer's yeast from a GLUTEN-FREE source (molasses-medium, not barley-derived).
- MAO inhibitor (classic MAOI, RIMA — moclobemide, isoniazid, linezolid) + ACTIVE (live) brewer's yeast: classic "cheese effect" — tyramine accumulation, hypertensive crisis. In inactivated form risk is lower, but caution advised.
- High purine intake (red meat, sardines, beer) + brewer's yeast regimen in gout: additive uric acid load.
- Celiac disease + barley-derived, traditional brewer's yeast: trace gluten — gluten-free source mandatory.
- Active Candida infection (medical diagnosis): caution — though S. cerevisiae taxonomically differs from Candida albicans, clinical practice advises caution.
- Saccharomyces boulardii probiotic simultaneously in duplicated regimen: unnecessary, dose confusion.
- In histamine sensitivity with long-stored or active yeast: can trigger symptoms.
- Severe kidney disease (CKD 4–5): protein and purine load.
- MAO inhibitor (classic MAOI or RIMA) treatment: ACTIVE yeast absolutely to be avoided; inactivated also cautiously.
- Active gout, hyperuricemia flare: high purine (300–500 mg/100 g) burdensome.
- Celiac disease, gluten sensitivity: barley-derived brewer's yeast to be avoided; gluten-free molasses-medium source acceptable.
- Active Crohn's disease, IBD flare: ASCA positivity is an immunological marker; individual intolerance common.
- Active Candida infection: caution (though taxonomically differs).
- Histamine intolerance: rare symptom.
- Pregnancy with ACTIVE (live) brewer's yeast: theoretical concern (fungal colonization); inactivated form generally safe.
- Severe kidney disease: protein and purine load.
- Immunocompromised patient with ACTIVE yeast: S. cerevisiae fungemia rare but reported.
Daily serving: 1–2 tablespoons (10–20 g) inactivated, debittered (flavor-mellowed) brewer's yeast powder.
Intake patterns:
- Smoothie: 1 tbsp brewer's yeast + banana + plant milk + 1 date (sweetening) + ½ tsp cinnamon.
- Yogurt/kefir: 1 tbsp stirred in + honey or berries.
- Into soup later: 1 tsp sprinkled (NOT cooked long — B vitamins are partly heat-labile).
- Tablet/capsule: old "brewer's yeast tablet" pharmacy format at 0.5 g per tablet, 4–8 per day.
- Classic "brewer's yeast pill" regimen (acne 8–12 weeks): 2 g per day, with food.
- Chromium GTF regimen for T2D support (medical supervision): brewer's yeast extract dosed per Anderson 1997 protocol.
Selection criteria:
- Inactivated (debittered) brewer's yeast powder for daily B-complex replacement.
- Gluten-free molasses-medium source for celiacs.
- Saccharomyces boulardii as a separate product for diarrhea/IBS purpose (Florastor, Enterol — NOT equivalent to classic brewer's yeast).
- B12 replacement separately — brewer's yeast is not enough.
Flavor masking: bitter flavor maskable with lemon, honey, fruit smoothie, intense-aroma matrices (cocoa, cinnamon).
Storage: as powder in cool, dry place, in the dark, 1 year stability.
What not to do: don't replace B12 with it (dangerous in vegan regimen). Don't combine with MAO inhibitor. Don't cook long.
References
[2597] Watanabe F et al. Vitamin B12-containing plant food sources for vegetarians. Nutrients 2014;6(5):1861–1873. . 2014. Link
The usual dietary sources of Vitamin B12 are animal-derived foods, although a few plant-based foods contain substantial amounts of Vitamin B12. To prevent Vitamin B12 deficiency in high-risk populations such as vegetarians, it is necessary to identify plant-derived foods that contain high levels of Vitamin B12. A survey of naturally occurring plant-derived food sources with high Vitamin B12 contents suggested that dried purple laver (nori) is the most suitable Vitamin B12 source presently available for vegetarians. Furthermore, dried purple laver also contains high levels of other nutrients that are lacking in vegetarian diets, such as iron and n-3 polyunsaturated fatty acids. Dried purple laver is a natural plant product and it is suitable for most people in various vegetarian groups.
[2600] Talbott S & Talbott J. Effect of BETA 1, 3/1, 6 GLUCAN on upper respiratory tract infection symptoms in marathon athletes. J Sports Sci Med 2009;8(4):509–515. . 2009. Link
A clinical trial (J Sports Sci Med) on the effect of BETA 1,3/1,6 GLUCAN on upper respiratory tract infection symptoms in marathon athletes. It evaluates beta-glucan supplementation and respiratory symptoms in athletes.
[2601] Choi HK et al. Purine-rich foods, dairy and protein intake, and the risk of gout in men. NEJM 2004;350(11):1093–1103. . 2004. Link
Journal article (NEJM, 2004) examining the association between purine-rich foods, dairy and protein intake, and the risk of gout in men.
[2604] Goldberger J et al. The transmissibility of pellagra: experimental attempts at transmission to the human subject. Public Health Reports 1916. . 1916. Link
Classic experimental report by Joseph Goldberger and colleagues on the transmissibility of pellagra, in which they attempted to transmit the disease to human subjects (volunteers, including Goldberger himself and close associates) using nasal secretions, scabs, blood, urine and feces from pellagra patients (via ingestion and intramuscular/subcutaneous injection). None of the transmission attempts succeeded, supporting that pellagra is not an infectious disease (but is of nutritional origin).
[2605] Elvehjem CA et al. Relation of nicotinic acid and nicotinic acid amide to canine black tongue. J Am Chem Soc 1937;59:1767–1768. . 1937. Link
Landmark paper by Elvehjem and colleagues (Madden, Strong, Woolley) demonstrating the relation of nicotinic acid (and nicotinic acid amide) to canine "black tongue" — the canine equivalent of pellagra. Nicotinic acid and its amide, isolated from liver extract, cured black tongue (a single ~30 mg dose of nicotinic acid produced a marked response), thereby identifying niacin as the anti-pellagra vitamin.
[2606] Anderson RA et al. Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes 1997;46(11):1786–1791. . 1997. Link
Chromium is an essential nutrient involved in normal carbohydrate and lipid metabolism. The chromium requirement is postulated to increase with increased glucose intolerance and diabetes. The objective of this study was to test the hypothesis that the elevated intake of supplemental chromium is involved in the control of type 2 diabetes. Individuals being treated for type 2 diabetes (180 men and women) were divided randomly into three groups and supplemented with: 1) placebo, 2) 1.92 micromol (100 microg) Cr as chromium picolinate two times per day, or 3) 9.6 micromol (500 microg) Cr two times per day. Subjects continued to take their normal medications and were instructed not to change their normal eating and living habits. HbA1c values improved significantly after 2 months in the group receiving 19.2 pmol (1,000 microg) Cr per day and was lower in both chromium groups after 4 months (placebo, 8.5 +/- 0.2\%; 3.85 micromol Cr, 7.5 +/- 0.2\%; 19.2 micromol Cr, 6.6 +/- 0.1\%).
[2607] Mertz W. Chromium in human nutrition: a review. J Nutr 1993;123(4):626–633. . 1993. Link
This review summarizes the results of 15 controlled studies supplementing defined Cr(III) compounds to subjects with impaired glucose tolerance. Three of these (3-4 mumol Cr/d for > 2 mo) produced no beneficial effects: serum glucose, insulin and lipid concentrations remained unchanged. The remaining 12 interventions improved the efficiency of insulin or the blood lipid profile of subjects (ranging from malnourished children and healthy middle-aged individuals to insulin-requiring diabetics). In addition, three cases of impaired glucose tolerance after long-term total parenteral alimentation responding to Cr supplementation have been reported. Chromium potentiates the action of insulin in vitro and in vivo; maximal in vitro activity requires a special chemical form, termed Glucose Tolerance Factor and tentatively identified as a Cr-nicotinic acid complex. Its complete structural identification is a major challenge to chromium research.
[2608] Weber G et al. Saccharomyces cerevisiae (CBS 5926) in acne vulgaris — clinical study. J Am Acad Dermatol 2012. . 2012.
Journal article reporting a clinical study (J Am Acad Dermatol, 2012) on Saccharomyces cerevisiae (CBS 5926) in acne vulgaris.
[2610] McFarland LV. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol 2010;16(18):2202–2222. . 2010. Link
This article reviews the evidence for efficacy and safety of Saccharomyces boulardii (S. boulardii) for various disease indications in adults based on the peer-reviewed, randomized clinical trials and pre-clinical studies from the published medical literature (Medline, Clinical Trial websites and meeting abstracts) between 1976 and 2009. For meta-analysis, only randomized, blinded controlled trials unrestricted by language were included. Pre-clinical studies, volunteer studies and uncontrolled studies were excluded from the review of efficacy and meta-analysis, but included in the systematic review. Of 31 randomized, placebo-controlled treatment arms in 27 trials (encompassing 5029 study patients), S. boulardii was found to be significantly efficacious and safe in 84\% of those treatment arms. A meta-analysis found a significant therapeutic efficacy for S. boulardii in the prevention of antibiotic-associated diarrhea (AAD) (RR = 0.47, 95\% CI: 0.35-0.63, P < 0.001). In adults, S. boulardii can be strongly recommended for the prevention of AAD and the traveler's diarrhea.
[2612] Anderson MC et al. Tyramine reactions and the cheese effect: MAO-inhibitor interactions. J Clin Psychiatry 1993. . 1993.
Journal article (J Clin Psychiatry, 1993) addressing tyramine reactions and the "cheese effect," i.e., interactions with MAO inhibitors.